NCT00676845

Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection

Effect of Olmesartan Medoxomil on Arterial Stiffness and Thickness in Subjects With Metabolic Syndrome

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 133 (actual)
• Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study will analyse the dose-dependent effect of olmesartan medoxomil on the change in arterial stiffness in subjects with hypertension and metabolic syndrome

Conditions

• Metabolic Syndrome
• Hypertension

Interventions

Type	Name	Description
DRUG	olmesartan medoxomil	dosage form: oral tablet; frequency: daily; duration: 52 weeks
DRUG	placebo	dosage form: tablet; frequency: daily; duration: 3 weeks
DRUG	olmesartan medoxomil	dosage form: oral tablet; frequency: daily; duration: 52 weeks
DRUG	olmesartan medoxomil	dosage form: oral tablet; frequency: daily; duration: 52 weeks

Timeline

• Start date: 2008-08-01
• Primary completion: 2011-05-01
• Completion: 2011-05-01
• First posted: 2008-05-13
• Last updated: 2018-12-24

Locations

3 sites across 3 countries: Belgium, Germany, Italy